Antigenic Hepatitis A Virus Structures May Be Produced in Escherichia coli

Glòria Sánchez, Santiago Caballero, Susana Guix, Albert Bosch,* and Rosa M. Pintó
Enteric Virus Laboratory, Department of Microbiology, University of Barcelona,
08028 Barcelona, Spain
Received 7 October 2002/Accepted 17 December 2002

The synthesis of 14S pentamers and 70S empty capsids of hepatitis A virus (HAV) has been accomplished by expressing the viral genome for periods of time longer than 4 h in Escherichia coli. HAV pentamers (14S) self-assembled into capsids (70S) in vitro. The antibodies induced by these structures recognized neutralized HAV.

The immunodominant neutralization antigenic site of the hepatitis A virus (HAV) is composed of closely related epitopes: some of them are detected on 14S pentameric subunits, while others are formed by structural changes during assembly of 14S structures into 70S and intact particles (9). Assembly of capsid proteins into subviral or virion structures might then be necessary for the generation of efficient HAV-neutralizing epitopes.

The expression of the complete open reading frame of the HAV genome in Escherichia coli gives mainly an insoluble fraction, containing the unprocessed P1 polypeptide (1), and a soluble fraction constituted by the processed structural proteins (5). To evaluate the usefulness of E. coli as an eventual expression system for the production of HAV structured antigens, antigenic and structural analysis of the viral maturation process was performed at different times postexpression (5).

E. coli strain JM109 harboring the pTHAVF plasmid, which expresses the complete HAV open reading frame, was grown on M9 medium supplemented with 0.4% glucose and 50 µg of ampicillin/ml. When the bacterial growth was at the beginning of the exponential phase (optical density at 600 nm [OD600], around 0.4), expression of the genome under the Tac promoter control was induced by addition of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). At different times postinduction, bacterial cells from 50 ml of culture were resuspended in TNE buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 7.4) and lysozyme treated (1 mg/ml) for 1 h. After three freeze-thawing cycles at −70°C, MgCl2 was added to achieve a final concentration of 10 mM and cell extracts were incubated with DNase I at a 10 µg/ml concentration at 4°C for 2 h. Two different fractions were recovered after centrifugation of the bacterial lysates at 11,000 × g for 10 min: an insoluble protein fraction, in the form of inclusion bodies (i.b.) corresponding to the pellet, and a soluble protein fraction corresponding to the supernatant.

The detection of HAV antigenic material in the soluble supernatant was performed by a direct enzyme-linked immunosorbent assay (ELISA), using a polyclonal murine ascitic antibody against intact HAV particles (anti-HAV) (4). Bacterial extracts from cultures harboring the pBTac-2 parental plasmid were used as negative controls. The soluble antigenicity increased over time (Table 1). This increment might be due either to an increase in the de novo synthesis of soluble antigenic material or to an antigenic maturation of the previously synthesized material. The bacterial growth was monitored by measuring the OD600 by counting the number of viable cells (in CFU per milliliter) on LB agar plates, and by counting the number of total cells (in cells per milliliter) after staining with the fluorochrome DAPI (4’,6’-diamidino-2-phenylindole), and it was observed that the viability of the pTHAVF-bearing recombinant strain declined after 4 h of induction (Fig. 1). Therefore, it was difficult to discern a real increase in the recombinant protein concentration. It has been recently postulated that i.b. are not merely irreversible accumulations of misfolded recombinant proteins but are reversible protein aggregations that release properly folded native proteins to the soluble cell compartment when protein synthesis is arrested (2, 3). Consequently, in experiments like ours, this phenomenon might lead to an increase in the concentration of those conformations able to produce subviral and viral structures.

To confirm the nature and the amount of the antigenic material, sucrose gradient analysis of the i.b.-free bacterial extracts was performed. A total of 500 µl of the soluble fraction extracted after the expression of pTHAVF was submitted to three cycles of sonication at 70 W for 30 s and was subsequently layered onto a 5 to 45% sucrose gradient in TNMg buffer (20 mM Tris-HCl, 10 mM NaCl, 50 mM MgCl2, pH 6.7) and spun at 205,000 × g for 165 min. Fractions (500 µl) were collected, and the presence of HAV antigenic material and refraction indices was determined for each fraction. HAV-related antigens were detected by a sandwich ELISA, consisting of HAV capture by human convalescent-phase serum 2 (HCS-2) (4), followed by detection with the 14S epitope-specific monoclonal antibody K2-4F2 (Commonwealth Serum Laboratories, Victoria, Australia). Sucrose gradient fractions of pBTac-2 bacterial extracts were used as negative controls. After 4 h of induction, two antigenic peaks with sedimentation coefficients of 14S and 70S were detected (Fig. 2A). After an 8-h induction, besides a significant increase in the 70S peak, two new antigenic peaks emerged, one around 5S...
and another between 14S and 70S (Fig. 2B). After 20 h of induction, the antigenic concentration greatly increased for all the peaks, taking into consideration that the 70S peak became a plateau (Fig. 2C).

To assay the maturation capability of some of the subviral structures, pooled sucrose fractions, corresponding to the 14S pentamers or 70S capsids purified from around 10^9 bacterial cells, were submitted to dialysis for sucrose removal, concentrated to a final volume of 500 µl by methanol precipitation, and layered onto a new gradient. The pooled 70S fractions gave the same 70S antigenic peak (data not shown). However, pooled 14S fractions resulted in the generation of both 14S and (mainly) 70S peaks (Fig. 3), demonstrating that self-assembly had occurred in vitro. That 14S structures self-assemble in vitro into 70S empty capsids has been described for poliovirus (6) and for recombinant HAV structures expressed in the vaccinia virus system (9). The other two peaks were not tested because of their unknown nature. The 5S peak might potentially correspond to protomers or merely to denatured HAV proteins.

Since the 14S pentamers self-assembled to 70S capsids, a total i.b.-free crude extract, containing in theory both 14S and (mainly) 70S structures, was administered to mice to test their immunogenic potential. The number of 70S capsids contained...
in these suspensions was estimated by immunoprecipitation-Western blotting (5), the threshold of sensitivity of this technique being $5 \times 10^7$ HAV particles. Since the direct bacterial crude supernatant (500 μl) used for the inoculation of mice was recorded as positive under this latter method and its 1/10 dilution was recorded as negative, we assumed that the titer in the supernatant was around $1 \times 10^7$ particles/ml. An i.b. preparation with a protein concentration of 100 mg/ml was sonicated in the presence of 0.5% sodium lauryl sulfate and was then administered to mice. Female Swiss mice (6 weeks old) were used to produce ascitic antibodies, after immunization with the different recombinant products employing Freund’s complete adjuvant (4). A total of 200 μg of protein per dose in the case of i.b., and around $2 \times 10^5$ recombinant particles per dose in the case of the supernatant product, was administered. Ascites generated by inoculation of phosphate-buffered saline were used as negative controls, while ascites generated by inoculation of $2 \times 10^7$ HAV intact particles per dose were used as positive controls. HAV recognition by the ascitic fluids was evaluated by a sandwich ELISA in which HAV was captured by the HCS-2 convalescent-phase serum and detected by the HAV detection was performed as described for Fig. 2.

This study was supported in part by grants QLRT-1999-0634 from the European Union, BIO95-0061 and BIO99-0455 from the CICYT, Ministry of Science and Technology, Spain, and 2001/SGR/00098 from the Generalitat de Catalunya and by the Centre de Biotecnologia de Catalunya (CrBBA), Generaltad de Catalunya.

REFERENCES


